XSB-001 Shows Equivalent Efficacy to Ranibizumab in nAMD Treatment

The analysis of the XPLORE trial suggested XSB-001 showed biosimilarity to reference ranibizumab as assessed by BCVA improvement at 8 weeks.

Related Keywords

Tel Aviv ,Israel , ,Tel Aviv Medical Center ,Drug Administration ,European Medicines Agency ,Eyepoint Pharmaceuticals Anat Loewenstein ,Eyepoint Pharmaceuticals ,Anat Loewenstein ,Tel Aviv Medical ,Early Treatment Diabetic Retinopathy Score ,United States ,